Experimental combo aims to fight Hard-to-Treat cancers
NCT ID NCT06468358
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests two experimental drugs, LB1410 and LB4330, given together to people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find safe doses and to see if the combination can shrink tumors or slow their growth. About 194 participants will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LB1410 (a drug that targets PD-1 and TIM3) and LB4330 (a drug that targets claudin18.2 and carries IL-10)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard options.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the combination may not prove effective or safe enough for wider use. Side effects from the immune-targeting drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 201114, China
Contact Phone: •••-•••-•••• Email: •••••@•••••